☆ 4.7 Article

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

NPJ PRECISION ONCOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC

Erica C. Nakajima et al.

Summary: The FDA has granted accelerated approval to sotorasib for the treatment of advanced non-small cell lung cancer with a KRAS G12C mutation. The drug has shown significant overall response rate and duration of response in clinical trials, with common adverse reactions including diarrhea and musculoskeletal pain.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

Sai-Hong Ignatius Ou et al.

Summary: This study reported the results of a clinical trial using adagrasib to treat non-small-cell lung cancer, colorectal cancer, and other solid tumors with the KRAS(G12C) mutation. The recommended phase II dose was identified as 600 mg twice a day, and it demonstrated good tolerability and antitumor activity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

Marwan G. Fakih et al.

Summary: Sotorasib, a specific inhibitor of KRAS(G12C) protein, showed modest anti-tumour activity and manageable safety in heavily pretreated patients with colorectal cancer in a phase 2 trial. The overall response rate of 9.7% did not reach the benchmark, but sotorasib is being evaluated in combination with other therapeutics to enhance potential activity and address potential resistance mechanisms.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti et al.

Summary: STK11 and KEAP1 mutations have a negative impact on the efficacy of immunotherapy in lung adenocarcinoma, but this effect is only observed in KRAS-positive tumors. Tumors with concurrent KRAS/STK11 and KRAS/KEAP1 mutations exhibit distinct immune characteristics.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors

Coren A. Milbury et al.

Summary: FoundationOne (R) CDx is an FDA-approved companion diagnostic test that utilizes comprehensive genomic profiling technology to analyze 324 cancer genes in solid tumors. It accurately identifies patients who may benefit from specific drug therapies and helps improve treatment outcomes for cancer patients.

PLOS ONE (2022)

添加到收藏夹

Article Medicine, General & Internal

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Pasi A. Jaenne et al.

Summary: Adagrasib demonstrated clinical efficacy without new safety signals in previously treated KRAS(G12C)-mutated NSCLC patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers

Mohamed E. Salem et al.

Summary: This study provides a comprehensive analysis of KRAS(G12C) mutations in various cancers, revealing its prevalence in females, older patients, and association with smoking status. KRAS(G12C) tumors exhibit distinct comutation profiles and are associated with high tumor mutational burden status.

JCO PRECISION ONCOLOGY (2022)

添加到收藏夹

Article Oncology

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition

Marco H. Hofmann et al.

Summary: Inhibiting SOS1, a KRAS activator and important feedback node, is an effective approach to treat KRAS-driven cancers. The highly potent and selective small-molecule SOS1 inhibitor, BI-3406, reduces cellular proliferation of KRAS-driven cancers by preventing the interaction with KRAS. Combination of SOS1 and MEK inhibition represents a novel and effective therapeutic concept for addressing KRAS-driven tumors.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Chemistry, Medicinal

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor

Xiaolun Wang et al.

Summary: KRAS(G12D), the most common oncogenic KRAS mutation, is a promising target for solid tumor treatment. Selective inhibition of KRAS(G12C) presents a significant challenge due to the requirement of high affinity inhibitors to bind the mutant protein. The discovery of the noncovalent, potent, and selective KRAS(G12C) inhibitor MRTX1133, shown to be efficacious in a mouse tumor model, represents a significant advancement in the field.

JOURNAL OF MEDICINAL CHEMISTRY (2021)

添加到收藏夹

Article Oncology

Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms

Hanna Tukachinsky et al.

Summary: Comprehensive genomic profiling (CGP) of cell-free circulating tumor DNA (ctDNA) is a promising approach for patients with metastatic castration-resistant prostate cancer (mCRPC), providing a minimally invasive alternative for detecting targetable genomic alterations. Analysis of ctDNA revealed a high concordance with tissue-based CGP, particularly in detecting BRCA1/2 mutations, while also identifying additional acquired resistance alterations. This highlights the potential of ctDNA as a clinical complement to tissue CGP, with reflex to tissue CGP in case of negative actionable variants.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Yulei Zhao et al.

Summary: Resistance to KRAS(G12C) inhibitors demonstrates a heterogeneous pattern with multiple subclonal events emerging during treatment. Co-targeting of ERK signaling intermediates can enhance the antiproliferative effect of G12C inhibitor treatment in models with acquired RAS or BRAF mutations.

NATURE (2021)

添加到收藏夹

Article Health Care Sciences & Services

Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States

Qianyi Zhang et al.

Summary: The study expanded the assessment of mortality variable and utilized a nationwide electronic health record database for data analysis. Compared with the National Death Index, the composite mortality variable showed high sensitivity, specificity, positive predictive value, negative predictive value, and +/- 15-day agreement across all 18 cancer types analyzed.

HEALTH SERVICES RESEARCH (2021)

添加到收藏夹

Article Oncology

Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes

Gabriela Palma et al.

Summary: Patients with tumors harboring KRAS G12C mutations have poor prognosis, but targeted therapies like sotorasib and Adagrasib have shown promising overall response rates. While single agent efficacy is observed, combination approaches may offer better outcomes.

NPJ PRECISION ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation

J. Weiss et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Acquired Resistance to KRASG12C Inhibition in Cancer

M. M. Awad et al.

Summary: A study of 38 patients with KRAS(G12C)-mutant cancers treated with adagrasib revealed diverse mechanisms of acquired resistance in 45% of them, including various mutations and bypass mechanisms. New therapeutic strategies are needed to overcome this drug resistance.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inibitor Response

Meagan Montesion et al.

Summary: The study uncovers the pan-cancer landscape of HLA-I LOH, showing an unexpected relationship between HLA-I LOH and TMB, and demonstrating HLA-I LOH as a significant negative predictor of outcomes after ICI treatment. These findings inform a combined predictor of outcomes after ICI and have implications for tumor vaccine development.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin et al.

CANCER DISCOVERY (2020)

添加到收藏夹

Review Oncology

The Frequency of Ras Mutations in Cancer

Ian A. Prior et al.

CANCER RESEARCH (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients

Dongsung Kim et al.

CELL (2020)

添加到收藏夹

Article Medicine, General & Internal

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Oncology

A compendium of mutational cancer driver genes

Francisco Martinez-Jimenez et al.

NATURE REVIEWS CANCER (2020)

添加到收藏夹

Article Medicine, General & Internal

Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database

Gaurav Singal et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

添加到收藏夹

Article Pathology

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples

Sally E. Trabucco et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2019)

添加到收藏夹

Article Biochemistry & Molecular Biology

A systems mechanism for KRAS mutant allele-specific responses to targeted therapy

Thomas McFall et al.

SCIENCE SIGNALING (2019)

添加到收藏夹

Article Cell Biology

Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D

Christian W. Johnson et al.

CELL REPORTS (2019)

添加到收藏夹

Article Oncology

Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy

Gerald Li et al.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, Research & Experimental

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

Andrew M. Waters et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)

添加到收藏夹

Article Pathology

Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Travis A. Clark et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2018)

添加到收藏夹

Article Oncology

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Article Biochemical Research Methods

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal

James X. Sun et al.

PLOS COMPUTATIONAL BIOLOGY (2018)

添加到收藏夹

Article Oncology

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer

Kathryn C. Arbour et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Ahmet Zehir et al.

NATURE MEDICINE (2017)

添加到收藏夹

Article Genetics & Heredity

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Zachary R. Chalmers et al.

GENOME MEDICINE (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

Nicholas McGranahan et al.

CELL (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Analysis of protein-coding genetic variation in 60,706 humans

Monkol Lek et al.

NATURE (2016)

添加到收藏夹

Article Medicine, General & Internal

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Eric Tran et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

A global reference for human genetic variation

David M. Altshuler et al.

NATURE (2015)

添加到收藏夹

Article Biochemical Research Methods

OptiType: precision HLA typing from next-generation sequencing data

Andras Szolek et al.

BIOINFORMATICS (2014)

添加到收藏夹

Article Multidisciplinary Sciences

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Jonathan M. Ostrem et al.

NATURE (2013)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

Garrett M. Frampton et al.

NATURE BIOTECHNOLOGY (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.